Vect-Horus
Designing and developing peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €5.3m Valuation: €33.5m 117.2x EV/Revenue -10.4x EV/EBITDA | Series D | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (87 %) | 30816 % | 41 % | (69 %) | 152 % | - | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (111289 %) | (270 %) | (276 %) | (1129 %) | (480 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (70589 %) | (112 %) | (163 %) | (756 %) | (340 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Vect-Horus is a biotechnology company focused on enhancing the delivery of therapeutic and imaging agents across biological barriers using its proprietary targeting technology. The company serves pharmaceutical and biotechnology firms by providing solutions that improve the efficacy and precision of drug delivery systems. Operating in the healthcare and life sciences market, Vect-Horus employs a business model that involves partnerships, licensing agreements, and collaborative research projects to generate revenue. By leveraging its innovative technology, Vect-Horus aims to address unmet medical needs and improve patient outcomes.
Keywords: biotechnology, drug delivery, targeting technology, therapeutic agents, imaging agents, pharmaceutical, biotechnology firms, healthcare, life sciences, partnerships.